About the Company

Heron Therapeutics (NasdaqCM: HRTX) is a specialty pharmaceutical company that develops products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company received FDA approval in August 2016 for its chemotherapy-induced nausea and vomiting (CINV) product Sustol (extended-release granisetron), and launched it in October. Lead clinical candidate Cinvanti (aprepitant) is in development for the prevention of CINV using the 505b(2) approval pathway. Cinvanti can be used in combination with Sustol, which could help to drive adoption of each. Heron filed and NDA for Cinvanti in January 2017, and expects a decision from the FDA in the fourth quarter of 2017. HTX-011 is a local anesthetic that utilizes a combined formulation of bupivacaine and meloxicam as a preventative treatment for post-operative pain. Promising Phase II data with HTX-011 has been seen across multiple surgery types, and the Company plans to begin Phase III studies in 2017 to support an FDA approval.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research